Abstract
Dry Powder Inhalation devices are currently used for the administration of inhaled Corticosteroids (ICS) and short acting B2 agonists (SABA). Most generic asthma medications are only available as Metered Dose Inhalers (MDI), with the consequence that Dry Powder Inhaler (DPI) devices are infrequently a therapeutic option in regions where medication costs are the overriding concern. Potential advantages of the DPI inhalation device as compared to MDI and nebulisation include; affordability, ease of use, reduced administration time and lack of CFC propellants. INTRODUCTION The aims of the study were to assess the bronchodilator efficacy and side effect profile of a low cost salbutamol DPI device when used in a busy Allergy Clinic. In addition, we sought to assess the attitudes of nursing staff, parents and patients, after having used the DPI device. METHODS For inclusion into the study, patients must have been able to activate the DPI through generating sufficient inspiratory flow. All consenting patients with clinical signs of asthma or if the FEV1 was 0.05. No patients required wet nebulisation. Adverse events reported were tremor in 4% and nausea in 8% of patients. Ninety eight percent of patients perceived the device easy to use and 94% of patients preferred the DPI to the MDI-Spacer combination. Ninety five percent of caregivers expressed confidence in the DPI device, were it to be required for the relief of acute asthma.
Paper version not known (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call